Limits...
Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors.

Liu RQ, Shen SJ, Hu XF, Liu J, Chen LJ, Li XY - Cancer Cell Int. (2013)

Bottom Line: The median survival was 12.2 months.Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors.HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.

View Article: PubMed Central - HTML - PubMed

Affiliation: First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. lixingyavip@163.com.

ABSTRACT

Aim: The incidence and mortality associated with intrahepatic cholangiocarcinoma is increasing in many countries and documentation of disease outcome is sparse. The present study was undertaken to investigate the prognostic factors for intrahepatic cholangiocarcinoma (ICC) following surgical resection. The impact of pre-existing HBV virus infection and adjuvant chemotherapy on the overall survival was also evaluated.

Methods: Clinical and pathological data were collected retrospectively from 81 patients undergoing surgery for ICC between 2005 and 2011, at The Henan Province Tumor Hospital and the First Affiliated Hospital of Zheng Zhou University. Survival and prognosis were analyzed using the Kaplan-Meier method and COX regression model.

Results: The population included 37 patients who were HBsAg + or anti-HBc+, 21 patients who were anti-HBs + positive and 18 patients who received adjuvant chemotherapy. The overall 1- and 3-year survival rates were 51% and 20%, respectively. The median survival was 12.2 months. Univariate analysis identified the following prognostic factors: HBV virus infection or HBV vaccine prior to resection (P = 0.017); adjuvant chemotherapy (P = 0.001); preoperative serum CA19-9 (> 200 U/mL; P = 0.015); GGT (> 64 U/L; P = 0.008), ALP (> 119 U/L; P = 0.01); lymph node metastasis (P = 0.005); radical resection (P = 0.021); intrahepatic metastasis (P = 0.015) and diabetes (P = 0.07). Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors.

Conclusions: HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.

No MeSH data available.


Related in: MedlinePlus

Overall survival rates after the surgical resection in 81 ICC patients, 3 groups according to the 5 markers of HBV in serum.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3852727&req=5

Figure 1: Overall survival rates after the surgical resection in 81 ICC patients, 3 groups according to the 5 markers of HBV in serum.

Mentions: The population was divided into three groups according to the serum HBV markers. The first group who were HBs-Ag or anti-HBc positive, represented patients with previous or current infection; the second group who were anti-HBs positive only, represented those with HBV infection or previous vaccination and the third group comprised patients with negative serum markers of HBV, who had never been infected with HBV. As shown in Figure 1 and Table 1, median survival was longer in patients who were anti-HBc and/or anti HBs positive (12 to 13 months) than in those with negative markers (6 months; P = 0.017). Survival among the eight HBsAb positive patients was similar to that among HBs-Ag or anti-HBc positive patients.


Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors.

Liu RQ, Shen SJ, Hu XF, Liu J, Chen LJ, Li XY - Cancer Cell Int. (2013)

Overall survival rates after the surgical resection in 81 ICC patients, 3 groups according to the 5 markers of HBV in serum.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3852727&req=5

Figure 1: Overall survival rates after the surgical resection in 81 ICC patients, 3 groups according to the 5 markers of HBV in serum.
Mentions: The population was divided into three groups according to the serum HBV markers. The first group who were HBs-Ag or anti-HBc positive, represented patients with previous or current infection; the second group who were anti-HBs positive only, represented those with HBV infection or previous vaccination and the third group comprised patients with negative serum markers of HBV, who had never been infected with HBV. As shown in Figure 1 and Table 1, median survival was longer in patients who were anti-HBc and/or anti HBs positive (12 to 13 months) than in those with negative markers (6 months; P = 0.017). Survival among the eight HBsAb positive patients was similar to that among HBs-Ag or anti-HBc positive patients.

Bottom Line: The median survival was 12.2 months.Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors.HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.

View Article: PubMed Central - HTML - PubMed

Affiliation: First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. lixingyavip@163.com.

ABSTRACT

Aim: The incidence and mortality associated with intrahepatic cholangiocarcinoma is increasing in many countries and documentation of disease outcome is sparse. The present study was undertaken to investigate the prognostic factors for intrahepatic cholangiocarcinoma (ICC) following surgical resection. The impact of pre-existing HBV virus infection and adjuvant chemotherapy on the overall survival was also evaluated.

Methods: Clinical and pathological data were collected retrospectively from 81 patients undergoing surgery for ICC between 2005 and 2011, at The Henan Province Tumor Hospital and the First Affiliated Hospital of Zheng Zhou University. Survival and prognosis were analyzed using the Kaplan-Meier method and COX regression model.

Results: The population included 37 patients who were HBsAg + or anti-HBc+, 21 patients who were anti-HBs + positive and 18 patients who received adjuvant chemotherapy. The overall 1- and 3-year survival rates were 51% and 20%, respectively. The median survival was 12.2 months. Univariate analysis identified the following prognostic factors: HBV virus infection or HBV vaccine prior to resection (P = 0.017); adjuvant chemotherapy (P = 0.001); preoperative serum CA19-9 (> 200 U/mL; P = 0.015); GGT (> 64 U/L; P = 0.008), ALP (> 119 U/L; P = 0.01); lymph node metastasis (P = 0.005); radical resection (P = 0.021); intrahepatic metastasis (P = 0.015) and diabetes (P = 0.07). Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors.

Conclusions: HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.

No MeSH data available.


Related in: MedlinePlus